Rybrevant SC 2240 mg/14 ml, Injektionslösung

7680698390022 CH-69839 Injektionslösung

No image available

Article details

Package size
1
Selling units
1
Measure
Durchstechflasche(n)
Galenic form
Injektionslösung
Galenic group
Injektion/Infusion

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
04/06/2026
Summary of Product Characteristics
Français
04/06/2026
Summary of Product Characteristics
Italien
04/06/2026

Detailed composition

Substance Quantity Type Category
amivantamabum
2240.0 MG Substance Wirkstoff (Principe actif)
hyaluronidasum humanum ADNr
- Substance HNIDK
natrii acetas trihydricus
- Substance HNIDK
acidum aceticum glaciale
- Substance HNIDK
saccharum
- Substance HNIDK
polysorbatum 80
- Substance HNIDK
methioninum
- Substance HNIDK
dinatrii edetas
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
8.66 MG Substance HBESI

Reimbursement information

Public price
CHF 5146.85
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/04/2026

Authorization holder

Janssen-Cilag AG

6300 Zug

Authorization information

Swissmedic authorization number
69839
Drug name
Rybrevant SC, Injektionslösung
Galenic form
LSINJ
ATC Code
L01FX18
Authorization status
Z
Dispensing category
A
First authorization
28/01/2026
Authorization expiration date
27/01/2031
IT Number
07.16.1.
Domain
Human medicine
Field of application
Nicht-kleinzelliges Lungenkarzinom, subkutane Injektion

Package details

Description (FR)
RYBREVANT SC 2240 mg/14 ml sol inj 2240 mg 1 pce
Description (DE)
RYBREVANT SC 2240 mg/14 ml Inj Lös 2240 mg 1 Stk
Market launch
20/02/2026
Narcotic (BTM)
No

Other package sizes (1)

RYBREVANT SC 1600 mg/10 ml sol inj 1600 mg 1 pce
1 DUR
GTIN: 7680698390015
View
Buy us a coffee Explore the data